Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
9.39
+0.03 (0.32%)
At close: Oct 29, 2025, 4:00 PM EDT
9.39
0.00 (0.00%)
After-hours: Oct 29, 2025, 4:00 PM EDT
Grifols Revenue
Grifols had revenue of 1.89B EUR in the quarter ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 7.45B, up 9.32% year-over-year. In the year 2024, Grifols had annual revenue of 7.21B with 9.41% growth.
Revenue (ttm)
7.45B EUR
Revenue Growth
+9.32%
P/S Ratio
0.92
Revenue / Employee
313,675 EUR
Employees
23,737
Market Cap
8.07B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GRFS News
- 20 days ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 23 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 26 days ago - Grifols: Significant Upside Likely Materializing - Seeking Alpha
- 5 months ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire
- 5 months ago - Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire
- 5 months ago - US court finds enough evidence to proceed with Grifols lawsuit against Gotham City - Reuters
- 5 months ago - Grifols: If This Works Out, It Has Massive Upside - Seeking Alpha
- 6 months ago - Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha